Research progress on myocarditis associated with immunotherapy in lung cancer

doi:10.3760/cma.j.cn371439-20251106-00051

Abstract

Abstract:

Immune checkpoint inhibitor treatment is an important treatment option for lung cancer. However， it can cause immune-related adverse events， including potentially severe cardiac toxicity， such as myocarditis， which can lead to treatment delays or discontinuation. Severe cardiac toxicity events can even result in patient death. Increasing attention to immune checkpoint inhibitor-associated myocarditis and implementing appropriate preventive and intervention measures for high-risk patients in clinical applications can minimize the risk and severity of myocarditis.

Key words: Lung neoplasms, Immune checkpoint inhibitors, Myocarditis

Zhao Juan, Yu Jiaofeng, Wei Aojiao, Dai Yixue, Zhao Yan, Fu Ye, Zhao Mingli. Research progress on myocarditis associated with immunotherapy in lung cancer[J]. Journal of International Oncology, 2026, 53(5): 311-316.

References 41

[1]	Yang HC, Chang A, Visa M, et al. Age-based screening for lung cancer surveillance in the US[J]. JAMA Netw Open, 2025, 8(11): e2546222. DOI: 10.1001/jamanetworkopen.2025.46222.
[2]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50[J]. J Clin Oncol, 2021, 39(21): 2339-2349. DOI: 10.1200/jco.21.00174.
[3]	严爱婷, 王翠竹, 刘春桂, 等. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142. DOI: 10.3760/cma.j.cn371439-20231109-00022.
[4]	Yau STY, Hung CT, Leung EYM, et al. The interactions among factors associated with the risk of lung cancer among diabetes patients: a survival tree analysis[J]. NPJ Prim Care Respir Med, 2025, 35(1): 20. DOI: 10.1038/s41533-025-00417-x.
[5]	Cheng XY, Long LZ, Li YZ, et al. Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study[J]. Sci Rep, 2025, 15(1): 35514. DOI: 10.1038/s41598-025-19460-2.
[6]	Li SS, Du F, Zhang Y, et al. Myocarditis prediction in locally advanced or metastatic lung cancer patients with cardiac parameters abnormalities undergoing immunotherapy: development and validation of a risk assessment model[J]. BMC Cancer, 2025, 25(1): 541. DOI: 10.1186/s12885-025-13943-1. pmid: 40133887
[7]	Axelrod ML, Meijers WC, Screever EM, et al. T cells specific for α- myosin drive immunotherapy-related myocarditis[J]. Nature, 2022, 611(7937): 818-826. DOI: 10.1038/s41586-022-05432-3.
[8]	Li S, Xu DZ, Murakoshi N, et al. Autoantibody profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study[J]. Front Immunol, 2024, 15: 1423622. DOI: 10.3389/fimmu.2024.1423622.
[9]	Liu XH, Wu W, Fang LG, et al. TNF-α inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis[J]. Front Immunol, 2022, 13: 922782. DOI: 10.3389/fimmu.2022.922782.
[10]	Stein-Merlob AF, Rothberg MV, Holman P, et al. Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies[J]. Curr Cardiol Rep, 2021, 23(3): 11. DOI: 10.1007/s11886-021-01440-3. pmid: 33483873
[11]	Dong H, Qi YH, Kong XY, et al. PD-1/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism[J]. Front Pharmacol, 2022, 13: 835510. DOI: 10.3389/fphar.2022.835510.
[12]	Michel L, Korste S, Spomer A, et al. PD1 deficiency modifies cardiac immunity during baseline conditions and in reperfused acute myocardial infarction[J]. Int J Mol Sci, 2022, 23(14): 7533. DOI: 10.3390/ijms23147533.
[13]	Xu L, Chen YK, Xiong L, et al. A review of immune checkpoint inhibitor-associated myocarditis: epidemiology, pathogenesis, and biomarkers[J]. Hum Vaccin Immunother, 2025, 21(1): 2512645. DOI: 10.1080/21645515.2025.2512645.
[14]	Wang C, Zhao G, Zhang Z, et al. Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports[J]. Front Immunol, 2023, 14: 1275254. DOI: 10.3389/fimmu.2023.1275254.
[15]	Liu Q, Yu YY, Lin JY, et al. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity[J]. Eur J Cancer, 2021, 157: 10-20. DOI: 10.1016/j.ejca.2021.07.023. pmid: 34464781
[16]	王秋实, 徐瑞涛, 李松, 等. 免疫检查点抑制剂相关多器官不良反应研究进展[J]. 国际肿瘤学杂志, 2024, 51(8): 510-514. DOI: 10.3760/cma.j.cn371439-20240515-00085.
[17]	Guo XX, Wang HP, Zhou JX, et al. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity[J]. Thorac Cancer, 2020, 11(2): 475-480. DOI: 10.1111/1759-7714.13250. pmid: 31849171
[18]	He YW, Chen WW, Cai JY, et al. PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients[J]. J Thorac Dis, 2023, 15(9): 4606-4619. DOI: 10.21037/jtd-23-596. pmid: 37868865
[19]	Chinese Society of Cardiology, Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Expert consensus statement on prevention and management of cancer therapy-related cardiac dysfunction[J]. Chin J Cardiol, 2025, 53(8): 855-871. DOI: 10.3760/cma.j.cn112148-20240816-00461.
[20]	Vasbinder A, Ismail A, Salem JE, et al. Role of biomarkers in the management of immune-checkpoint inhibitor-related myocarditis[J]. Curr Cardiol Rep, 2023, 25(9): 959-967. DOI: 10.1007/s11886-023-01915-5. pmid: 37436648
[21]	于坚, 刘新亚, 王江涛, 等. 免疫检查点抑制剂相关性心肌炎患者NLR、PLR、MPVLR、SII水平变化及其临床意义[J]. 临床心血管病杂志, 2024, 40(9): 737-741. DOI: 10.13201/j.issn.1001-1439.2024.09.009.
[22]	Gao YY, Zhang HD, Qiu YL, et al. Early identification of severe immune checkpoint inhibitor associated myocarditis: from an electrocardiographic perspective[J]. Cancer Med, 2024, 13(15): e7460. DOI: 10.1002/cam4.7460.
[23]	Zotova L. Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases[J]. Diagnostics (Basel), 2023, 13(7): 1243. DOI: 10.3390/diagnostics13071243.
[24]	Xu Y, Song YJ, Liu XY, et al. Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis[J]. Cancer Commun (Lond), 2022, 42(9): 902-905. DOI: 10.1002/cac2.12320.
[25]	Zhang LL, Zlotoff DA, Awadalla M, et al. Major adverse cardio-vascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis[J]. Circulation, 2020, 141(24): 2031-2034. DOI: 10.1161/circulationaha.119.044703. pmid: 32539614
[26]	Smiseth OA, Morris DA, Cardim N, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the european association of cardiovascular imaging[J]. Eur Heart J Cardiovasc Imaging, 2022, 23(2): e34-e61. DOI: 10.1093/ehjci/jeab154.
[27]	Sławiński G, Hawryszko M, Liżewska-Springer A, et al. Global longitudinal strain in cardio-oncology: a review[J]. Cancers (Basel), 2023, 15(3): 986. DOI: 10.3390/cancers15030986.
[28]	Zhang LL, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis[J]. Eur Heart J, 2020, 41(18): 1733-1743. DOI: 10.1093/eurheartj/ehaa051. pmid: 32112560
[29]	Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2022, 43(41): 4229-4361. DOI: 10.1093/eurheartj/ehac244. pmid: 36017568
[30]	Lucinian YA, Martineau P, Abikhzer G, et al. Novel tracers to assess myocardial inflammation with radionuclide imaging[J]. J Nucl Cardiol, 2024, 42: 102012. DOI: 10.1016/j.nuclcard.2024.102012.
[31]	Boughdad S, Latifyan S, Fenwick C, et al. ⁶⁸Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis[J]. J Immunother Cancer, 2021, 9(10): e003594. DOI: 10.1136/jitc-2021-003594.
[32]	Finke D, Heckmann MB, Herpel E, et al. Early detection of checkpoint inhibitor-associated myocarditis using ⁶⁸Ga-FAPI PET/CT[J]. Front Cardiovasc Med, 2021, 8: 614997. DOI: 10.3389/fcvm.2021.614997.
[33]	Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment[J]. J Am Heart Assoc, 2020, 9(2): e013757. DOI: 10.1161/jaha.119.013757.
[34]	Wu YH, Xu YZ, Xu LH. Drug therapy for myocarditis induced by immune checkpoint inhibitors[J]. Front Pharmacol, 2023, 14: 1161243. DOI: 10.3389/fphar.2023.1161243.
[35]	Wadden E, Lai C, Grivas P, et al. Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report[J]. Eur Heart J Case Rep, 2025, 9(2): ytaf019. DOI: 10.1093/ehjcr/ytaf019.
[36]	Tan SH, Qi C, Zeng H, et al. Steroid-refractory myocarditis induced by immune checkpoint inhibitor responded to infliximab: report of two cases and literature review[J]. Cardiovasc Toxicol, 2024, 24(11): 1174-1191. DOI: 10.1007/s12012-024-09918-6. pmid: 39256296
[37]	Zhang RS, Padegimas A, Murphy KM, et al. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Inflixi-mab: a case series[J]. Cardiooncology, 2021, 7(1): 13. DOI: 10.1186/s40959-021-00095-x.
[38]	Doms J, Prior JO, Peters S, et al. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis[J]. Ann Oncol, 2020, 31(9): 1273-1275. DOI: 10.1016/j.annonc.2020.05.005. pmid: 32425357
[39]	Suda Y, Ikuta K, Hayashi S, et al. Comparison of anti-inflammatory and anti-angiogenic effects of JAK inhibitors in IL-6 and TNFα- stimulated fibroblast-like synoviocytes derived from patients with RA[J]. Sci Rep, 2025, 15(1): 9736. DOI: 10.1038/s41598-025-94894-2.
[40]	Liu GH, Chen T, Zhang X, et al. Immune checkpoint inhibitor-associated cardiovascular toxicities: a review[J]. Heliyon, 2024, 10(5): e25747. DOI: 10.1016/j.heliyon.2024.e25747.
[41]	Zhang H, Lin JY, Shen YH, et al. Protective effect of crocin on immune checkpoint inhibitors-related myocarditis through inhibiting NLRP3 mediated pyroptosis in cardiomyocytes via NF-κB pathway[J]. J Inflamm Res, 2022, 15: 1653-1666. DOI: 10.2147/jir.S348464. pmid: 35282269